Physician profile
Michael Tan
NPI 1669499208
$2,719.11
in general payments reported to CMS, 2019-2025
29 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $731 · 2021: $399 · 2022: $185 · 2023: $117 · 2024: $347 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.17 |
| Education | $132.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $524.91 | 2019-2021 | |
| Novo Nordisk INC | $370.27 | 2019-2025 | Ozempic |
| Sunovion Pharmaceuticals INC. | $362.02 | 2019-2022 | |
| Ucb, INC. | $243.18 | 2024-2025 | Bimzelx, Briviact, Rystiggo |
| Abiomed | $199.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $113.35 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $82.61 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $80.13 | 2023-2024 | Gemtesa |
| Biogen, INC. | $80.11 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $72.65 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $69.64 | 2020-2021 | |
| Amarin Pharma, INC. | $61.89 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.59 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $48.52 | 2019-2024 | Eliquis |
| Glaxosmithkline, LLC. | $45.16 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.39 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $41.27 | 2024-2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $34.62 | 2025 | Nuzyra |
| Radius Health, INC. | $29.17 | 2020 | |
| Neurocrine Biosciences, INC. | $26.29 | 2025 | |
| Abbott Laboratories | $19.77 | 2021 | |
| Boston Scientific Corporation | $19.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.54 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.92 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.87 | 2019 | |
| Lilly USA, LLC | $15.53 | 2020 | |
| Eisai INC. | $14.22 | 2021 | |
| Abbvie INC. | $13.34 | 2021 | |
| Allergan, INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.